LEXINGTON, Mass., Dec. 16, 2021 /PRNewswire/ -- iSpecimen
Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online
marketplace for human biospecimens, today announced that it
has expanded its global supplier network, with 25% of its newest
specimen suppliers in 2021 coming from outside the United States. The expansion enhances the
value of iSpecimen's federated network of human biospecimen
suppliers for research, now with more than 200 suppliers
participating in the iSpecimen Marketplace. Throughout 2021,
iSpecimen has added nearly two dozen biospecimen suppliers to its
network, across the United States
and Europe, augmenting its
existing network that also includes suppliers in Asia-Pacific.
"Our expanded global coverage creates a strong foundation for
international growth," said iSpecimen Founder and
CEO, Christopher Ianelli, MD, Ph.D. "We're seeing more demand
for biospecimens in Europe and
Asia-Pacific, so it's important to
have the supply there as well. Ultimately, we're providing research
organizations everywhere in the world with a more diverse selection
of specimens from more varied populations of patients, equipping
researchers with the collections they need to expedite their
work."
iSpecimen's expanded global coverage better serves life science
research organizations by:
- Enabling researchers around the world to procure biospecimens
from close to their labs, which is especially critical during
global supply chain disruptions.
- Expanding biospecimen access in regions including Germany, Russia, South
America, Ukraine,
Bulgaria, Spain, and India to further support medical research in
conditions such as autoimmune diseases, various cancers, digestive
disorders, endocrine system disorders, cardiovascular
disorders, pregnancy (normal, high risk, fetal abnormalities),
pulmonary/respiratory tract disorders, and skin and connective
tissue disorders.
- Providing researchers with a wider range of biofluids, tissue,
and stem and immune cells than are available in their local
geographies, including specimens with genetic variants (such as
COVID-19 variants) that are more prevalent in those regions.
- Making available biospecimens that reflect diseases that are
limited to certain regions of the world, or that are treated
differently in those regions.
- Directly addressing the multinational procurement needs of
global research organizations.
Streamlining Biospecimen Procurement
Estimates from
the Office of Biorepositories and Biospecimen Research reported in
2011 and iSpecimen's survey of researchers performed in 2019
indicate that 4 in 5 researchers have limited the scope of their
work due to the shortage of quality biospecimens. To address this
challenge and accelerate scientific discovery, the iSpecimen
Marketplace connects life science researchers who need
biospecimens with patients and healthcare organizations that
can provide them. The iSpecimen Marketplace automates search,
selection, contracting, compliance/ethics (institutional review
board) audits, quoting, order management, invoicing, and more.
About iSpecimen
iSpecimen offers an online marketplace
for human biospecimens, connecting life scientists in commercial
and non-profit organizations with healthcare providers that have
access to patients and specimens needed for medical discovery.
Proprietary, cloud-based technology enables scientists to
intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss / Scott Eckstein
iSpecimen@kcsa.com
Media Contact
Kaitlynn
Cooney
For iSpecimen
kcooney@brodeur.com
617.587.2811
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ispecimen-expands-global-biospecimen-supplier-network-broadening-footprint-around-the-world-301446000.html
SOURCE iSpecimen Inc.